Decision-making and impulsivity in cabergoline-treated prolactinoma: findings from Iowa Gambling, Go/No-Go, and barratt scales
Authors' conclusion
In patients with prolactinoma, dopamine agonist treatment is associated with selective alterations in decision-making-related impulsivity and inhibitory control, influenced by treatment duration and cumulative dopamine agonist exposure.
Study context
- Population
- Patients with prolactinoma treated with dopamine agonists and healthy controls
- Participants
- 34 vs 35
- Exposure
- Prolactinoma patients on dopamine agonists (DA) therapy vs healthy controls
- Prolactinoman = 34
- Healthy control (HC)n = 35reference
- Outcome
- Impulsivity, decision-making and inhibitory control
Main finding
As reported in the abstract
- Prolactinoma vs HC: P = 0.003 for both
- Between Prolactinoma and HC: P = 0.041
Observational data: associations, not effects.
Further findings
Correlations with treatment duration
- Treatment duration vs frequency of sexual desire (past 4 weeks)
- r = 0.364, p = 0.035
- Treatment duration vs Barratt Impulsiveness Scale-Short Form (BIS-11-SF) non-planning subscale
- r = 0.429, p = 0.011
Correlations with cumulative DA dose
- Cumulative DA dose vs frequency of sexual desire
- r = 0.405, p = 0.018
- Cumulative DA dose vs frequency of sexual intercourse attempts (past 4 weeks)
- r = 0.433, p = 0.011
- Cumulative DA dose vs BIS-11-SF non-planning subscale
- r = 0.418, p = 0.014
Original publication
Decision-making and impulsivity in cabergoline-treated prolactinoma: findings from Iowa Gambling, Go/No-Go, and barratt scales. Pituitary. Published 30 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →